BTI cuts red ink as sales boom
Biomagnetic Technologies of San Diego reported a sharp increase in sales and a lower net loss for fiscal 1997 (end-September) as the company began recognizing revenue from magnetic source imaging systems that had been delayed from shipping in 1996. BTI
Biomagnetic Technologies of San Diego reported a sharp increase in sales and a lower net loss for fiscal 1997 (end-September) as the company began recognizing revenue from magnetic source imaging systems that had been delayed from shipping in 1996. BTI also reported that a European customer is developing a new version of its Magnes technology for applications other than the brain.
For the year, BTI posted revenues of $11 million, compared with $1.4 million in fiscal 1996, while the company's net loss shrank to $3 million, compared with $14.8 million the year before. BTI's revenues for the year included sales from the company's first Magnes 1300C system, which is being developed at the European site.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
